THC Global Group (ASX:THC) has completed the first farm-to-pharma processing of medicinal cannabis in Australia at its Southport manufacturing facility (pictured) in Queensland.
The Southport Facility is the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere and is licenced and permitted to process medicinal cannabis.
THC Global CEO Ken Charteris said: “Completing this Australian farm to Australian pharma production process going from cultivation at our Bundy Cultivation facility through to our Southport Facility provides clear validation of our capability.
“THC Global has ready-to-go production assets within Australia capable of servicing over 250,000 patients in addition to the global export market.”
THC Global’s Southport Facility is capable of producing TGA certified pharmaceutical GMP finished product, enabling the Company to supply its medicinal cannabis products to patients in Australia and in export markets.
The company is marketing its Canndeo branded medicinal cannabis products, as well as offering services in high value add extraction and cultivation using its “low cost Australian cultivation facilities”.
This first production was completed using its proprietary Australian high-CBD cannabis strain.
Picture: THC Global
Subscribe to our free @AuManufacturing newsletter here.